RVPH vs RXRX

Reviva Pharmaceuticals Holdings vs Recursion Pharmaceuticals, Inc. — Valuation Comparison 2026

RVPH

Biotechnology
Reviva Pharmaceuticals Holdings
Quality
3.7
out of 10
Value Trap
24
SAFE
Price
$0.43
Last close
Models
5/13
Active
VS

RXRX

Biotechnology
Recursion Pharmaceuticals, Inc.
Quality
6.5
out of 10
Value Trap
37
LOW
Price
$3.44
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType RVPH Fair ValueRVPH Upside RXRX Fair ValueRXRX Upside
Bayesian DCF Intrinsic $1.03 +142.9% $1.52 -55.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.03 -96.6% $0.04 -98.9%
Dynamic NAV Asset-Based $1.99 -42.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RVPH vs RXRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RVPH vs RXRX — Which Stock Is More Undervalued?

RXRX scores higher with a 6.5/10 quality rating vs RVPH's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Reviva Pharmaceuticals Holdings (RVPH) and Recursion Pharmaceuticals, Inc. (RXRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RVPH currently trades at $0.43 with a QOC of 3.7/10, while RXRX trades at $3.44 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).